13,056 results on '"Diuretics therapeutic use"'
Search Results
2. Clinical Outcomes of Metabolic Surgery on Diuretic Use in Patients With Heart Failure.
- Author
-
Kachmar M, Corpodean F, LaChute C, Popiv I, Cook MW, Danos DM, Albaugh VL, Moraes DL, Tang WHW, and Schauer PR
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Retrospective Studies, Weight Loss, Glycated Hemoglobin metabolism, Treatment Outcome, Body Mass Index, Emergency Service, Hospital statistics & numerical data, Heart Failure, Diuretics therapeutic use
- Abstract
The beneficial impacts of metabolic surgery (MS) on patients with heart failure (HF) are incompletely characterized. We aimed to describe the cardiac and metabolic effects of MS in patients with HF and hypothesized that patients with HF would experience both improved metabolic and HF profiles using glycemic control and diuretic dependency as surrogate markers. In this single-center, university-affiliated academic study in the United States, a review of 2,342 hospital records of patients who underwent MS (2017 to 2023) identified 63 patients with a medical history of HF. Preoperative characteristics, 30-day outcomes, and up to 2-year biometric and metabolic outcomes, medication usage, and emergency department utilization were collected. At 24 months, mean body mass index change was -16 kg/m
2 (p <0.001) that corresponded to a mean percentage total body weight loss of 29% (p <0.001). Weight loss was accompanied by significant reductions in hemoglobin A1c (p <0.001) and a 65% decrease in diuretic use at 24 months after surgery (p <0.001). Similarly, emergency visits for cardiac conditions (p = 0.06) and intravenous diuresis (p = 0.07) trended favorably at 1 year after surgery compared with 1 year before surgery but were not statistically significant. In conclusion, in patients with HF who were carefully selected, MS appears to provide significant reduction in oral diuretic dependency, and metabolic improvements with trends toward lower rates of emergency department utilization., Competing Interests: Declaration of competing interest Dr. Tang has served as consultant for Sequana Medical, Cardiol Therapeutics, Genomics plc, Zehna Therapeutics, WhiteSwell, Kiniksa Pharmaceuticals, Boston Scientific, CardiaTec Biosciences, Intellia Therapeutics, Bristol-Myers Squibb, Alleviant Medical, Alexion Pharmaceuticals, Salubris Biotherapeutics, and BioCardia, and has received honoraria from Springer, Belvoir Media Group, and American Board of Internal Medicine. Dr. Cook has served as consultant for Asensus Surgical, Intuitive Surgical, and Vicarious Surgical. Dr. Schauer reports receiving research grants from Ethicon and Medtronic; receiving personal consulting fees or honoraria from GI Dynamics; Keyron; Persona; Mediflix, Metabolic Health International, LTD, Lilly, Heron, Novo Nordisk, Klens; serving on scientific advisory boards for SE Healthcare Board of Directors; GI Dynamics ; Keyron; Persona; Mediflix, and having ownership interest in SE Healthcare LLC, Mediflix, Metabolic Health International, LTD. The remaining authors have no competing interests to declare., (Copyright © 2024 Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
3. Acetazolamide therapy in patients with acute heart failure: a systematic review and meta-analysis of randomized controlled trials.
- Author
-
Milbradt TL, Sudo RYU, Gobbo MODS, Akinfenwa S, and Moura B
- Subjects
- Humans, Acute Disease, Carbonic Anhydrase Inhibitors therapeutic use, Treatment Outcome, Aged, Acetazolamide therapeutic use, Heart Failure drug therapy, Heart Failure physiopathology, Heart Failure mortality, Randomized Controlled Trials as Topic, Diuretics therapeutic use
- Abstract
Acute heart failure (AHF) often leads to unfavorable outcomes due to fluid overload. While diuretics are the cornerstone treatment, acetazolamide may enhance diuretic efficiency by reducing sodium reabsorption. We performed a systematic review and meta-analysis on the effects of acetazolamide as an add-on therapy in patients with AHF compared to diuretic therapy. PubMed, Embase, and Cochrane databases were searched for randomized controlled trials (RCT). A random-effects model was employed to compute mean differences and risk ratios. Statistical analysis was performed using R software. The GRADE approach was used to rate the certainty of the evidence. We included 4 RCTs with 634 patients aged 68 to 81 years. Over a mean follow-up of 3 days to 34 months, acetazolamide significantly increased diuresis (MD 899.2 mL; 95% CI 249.5 to 1549; p < 0.01) and natriuresis (MD 72.44 mmol/L; 95% CI 39.4 to 105.4; p < 0.01) after 48 h of its administration. No association was found between acetazolamide use and WRF (RR 2.4; 95% CI 0.4 to 14.2; p = 0.3) or all-cause mortality (RR 1.2; 95% CI 0.8 to 1.9; p = 0.3). Clinical decongestion was significantly higher in the intervention group (RR 1.35; 95% CI 1.09 to 1.68; p = 0.01). Acetazolamide is an effective add-on therapy in patients with AHF, increasing diuresis, natriuresis, and clinical decongestion, but it was not associated with differences in mortality., (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
4. Utility of fractional excretion of urea in acute kidney injury with comparison to fractional excretion of sodium: A systematic review and meta-analysis.
- Author
-
Abdelhafez MO, Alhroob AA, Abu Hawilla MO, Rjoob AA, Abualia NM, Gorman EF, Hamadah AM, and Gharaibeh KA
- Subjects
- Humans, Diuretics therapeutic use, Acute Kidney Injury diagnosis, Acute Kidney Injury drug therapy, Acute Kidney Injury metabolism, Sodium urine, Urea urine
- Abstract
Background: Differentiating between intrinsic and prerenal acute kidney injury (AKI) presents a challenge. Here, we assessed the performance of the fractional excretion of urea (FEUrea) and compared it to the fractional excretion of sodium (FENa) in distinguishing intrinsic from prerenal AKI., Methods: A thorough search was conducted in several databases until January 16, 2024. We included studies evaluating FEUrea, with or without FENa, for differentiating AKI etiologies in adults. We assessed the methodological quality using the QUADAS-2 and QUADAS-C tools. We performed a meta-analysis using the bivariate random effects model, with subgroup analyses to explore the impact of diuretic therapy on FEUrea, and direct statistical comparisons between FEUrea and FENa involving the subgroups with and without diuretics., Results: We included 11 studies with 1108 hospitalized patients. Among eight studies (915 patients) evaluating FEUrea >35% for distinguishing intrinsic from prerenal AKI, the pooled sensitivity and specificity were 66% (95% CI, 49%-79%) and 75% (95% CI, 60%-85%), respectively. In a subset of six studies (302 patients) comparing FEUrea at 35% to FENa at 1% in patients not receiving diuretics, there were no significant differences in sensitivity (77% versus 89%, P = 0.410) or specificity (80% versus 79%, P = 0.956). In four studies, 244 patients on diuretics, FEUrea demonstrated lower sensitivity (52% versus 92%, P < 0.001) but higher specificity (82% versus 44%, P < 0.001) compared to FENa for the diagnosis of intrinsic AKI., Conclusions: FEUrea has limited utility in differentiating intrinsic from prerenal AKI. FEUrea does not provide a superior alternative to FENa, even in patients receiving diuretics., Competing Interests: Declaration of competing interest All authors have nothing to disclose., (Copyright © 2024 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
5. Clinical management of unremitting nephrogenic diabetes insipidus.
- Author
-
Elavia N, Weir MR, Haririan A, and Khan SH
- Subjects
- Humans, Male, Diuretics therapeutic use, Quality of Life, Female, Diabetes Insipidus, Nephrogenic diagnosis, Diabetes Insipidus, Nephrogenic therapy, Diabetes Insipidus, Nephrogenic complications
- Abstract
The polyuria and polydipsia state in diabetes insipidus (DI) can be challenging to manage for patients and clinicians with significant impact on the patients' well-being. A review of literature shows that nonsteroidal anti-inflammatory drugs (NSAIDs), thiazide and potassium-sparing diuretics, along with low dietary solute and protein, and high water intake remain the standard medical therapy. Although these therapeutic approaches improve symptoms, the urine-concentrating defect is still considerable, posing a serious risk to patient's life from hypovolemia if high fluid intake is not maintained. Our case describes the challenges faced with the medical management of a patient with nephrogenic DI that was only partially responsive to standard medical therapy, resulting in debilitating effects on the patient's quality of life.
- Published
- 2024
- Full Text
- View/download PDF
6. Diuretic response after neonatal cardiac surgery: a report from the NEPHRON collaborative.
- Author
-
Blinder JJ, Alten J, Bailly D, Buckley J, Clarke S, Diddle JW, Garcia X, Gist KM, Koch J, Kwiatkowski DM, Rahman AKMF, Reichle G, Valentine K, Hock KM, and Borasino S
- Subjects
- Humans, Retrospective Studies, Male, Female, Infant, Newborn, Length of Stay statistics & numerical data, Registries statistics & numerical data, Respiration, Artificial statistics & numerical data, Postoperative Complications etiology, Postoperative Complications epidemiology, Postoperative Complications prevention & control, Infant, ROC Curve, Treatment Outcome, Cardiac Surgical Procedures adverse effects, Diuretics administration & dosage, Diuretics therapeutic use, Acute Kidney Injury etiology, Acute Kidney Injury diagnosis, Furosemide administration & dosage
- Abstract
Background: Multicenter early diuretic response (DR) analysis of single furosemide dosing following neonatal cardiac surgery is lacking to inform whether early DR predicts adverse clinical outcomes., Methods: We performed a retrospective cohort study utilizing data from the NEPHRON registry. Random forest machine learning generated receiver operating characteristic-area under the curve (ROC-AUC) and odds ratios for mechanical ventilation (MV) and respiratory support (RS). Prolonged MV and RS were defined using ≥ 90th percentile of observed/expected ratios. Secondary outcomes were prolonged CICU and hospital length of stay (LOS) and kidney failure (stage III acute kidney injury (AKI), peritoneal dialysis, and/or continuous kidney replacement therapy on postoperative day three) assessed using covariate-adjusted ROC-AUC curves., Results: A total of 782 children were included. Cumulative urine output (UOP) metrics were lower in prolonged MV and RS patients, but DR poorly predicted prolonged MV (highest AUC 0.611, OR 0.98, sensitivity 0.67, specificity 0.53, p = 0.006, 95% OR CI 0.96-0.99 for cumulative 6-h UOP) and RS (highest AUC 0.674, OR 0.94, sensitivity 0.75, specificity 0.54, p < 0.001, 95% CI 0.91-0.97 UOP between 3 and 6 h). Secondary outcome results were similar. DR had fair discrimination for kidney failure (AUC 0.703, OR 0.94, sensitivity 0.63, specificity 0.71, 95% OR CI 0.91-0.98, p < 0.001, cumulative 6-h UOP)., Conclusions: Early DR poorly discriminated patients with prolonged MV, RS, and LOS in this cohort, though it may identify severe postoperative AKI phenotype. Future work is warranted to determine if early DR or late postoperative DR later, in combination with other AKI metrics, may identify a higher-risk phenotype., (© 2024. The Author(s), under exclusive licence to International Pediatric Nephrology Association.)
- Published
- 2024
- Full Text
- View/download PDF
7. Carbohydrate antigen 125-guided pre-TAVI medical optimization: impact on quality of life and clinical outcomes.
- Author
-
García-Blas S, Pernias V, González D'Gregorio J, Fernández-Cisnal A, Bonanad C, Sastre C, Valero E, Miñana G, Zaharia G, Núñez J, and Sanchis J
- Subjects
- Humans, Male, Female, Prospective Studies, Aged, 80 and over, Biomarkers blood, Diuretics therapeutic use, Treatment Outcome, Aged, Follow-Up Studies, Quality of Life, CA-125 Antigen blood, Transcatheter Aortic Valve Replacement methods, Aortic Valve Stenosis surgery
- Abstract
Introduction and Objectives: Carbohydrate antigen 125 (CA125), a biomarker associated with fluid overload, has proven useful in managing diuretic therapy in heart failure. We aimed to evaluate the impact of diuretic optimization guided by CA125 before transcatheter aortic valve implantation (TAVI) on outcomes., Methods: This prospective interventional study enrolled patients scheduled for TAVI, in whom baseline CA125 was measured 2 weeks before TAVI. Patients with CA125 ≥ 20 U/mL underwent diuretic up-titration before TAVI. Three groups were included: group I) baseline CA125 <20 U/mL; IIa) CA125 ≥ 20 U/mL that decreased after treatment, and IIb) CA125 ≥ 20 U/mL that did not decrease. The primary outcome was changes in the Kansas City Cardiomyopathy Questionnaire at 3 and 12 months. The secondary endpoint was clinical events., Results: The study included 184 patients (115 group I, 46 IIa, and 23 IIb). Groups I and IIa exhibited early and sustained improvements in the Kansas City Cardiomyopathy Questionnaire (group I: 18.9 points [95%CI, 15.7-22.1; P <.001] at 90 days, and 18.1 [95%CI, 14.9-21.4, P <.001] at 1 year; group IIa: 21.1 points [95%CI, 15.4-26.7; P <.001] and 19.5 [95%CI, 13.9-25.1; P <.001] respectively). In contrast, in group IIb there was no significant improvement at 90 days (P=.12), with improvement being significant only at 1 year (17.8 points, 95%CI, 5.9-29.6; P=.003). Over a median follow-up of 20.7 months, there were 63 (27.83%) deaths or heart failure admissions. Multivariate analysis showed a lower risk of events in group I vs IIb (HR, 0.28; 95%CI, 0.14-0.58; P <.001), and IIa vs IIb (HR, 0.24; 95%CI, 0.11-0.55; P <.001)., Conclusions: Patients with persistently high CA125 despite diuretic therapy pre-TAVI showed slower functional recovery and poorer clinical outcomes after TAVI., (Copyright © 2024 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
8. Full decongestion in acute heart failure therapy.
- Author
-
Buttar C, Alai H, Matanes FN, Cassidy MM, Stencel J, and Le Jemtel TH
- Subjects
- Humans, Acute Disease, Adrenergic beta-Antagonists therapeutic use, Mineralocorticoid Receptor Antagonists therapeutic use, Sodium-Glucose Transporter 2 Inhibitors therapeutic use, Diuretics therapeutic use, Angiotensin Receptor Antagonists therapeutic use, Heart Failure drug therapy
- Abstract
Incomplete decongestion is the main cause of readmission in the early post-discharge period of a hospitalization for acute heart failure. Recent heart failure guidelines have highlighted initiation and rapid up-titration of quadruple therapy with angiotensin receptor neprilysin inhibitor, beta adrenergic receptor blocker, mineralocorticoid receptor antagonist, and sodium glucose cotransporter 2 inhibitor to prevent hospitalizations for heart failure with reduced ejection fraction. However, full decongestion remains the foremost therapeutic goal of hospitalization for heart failure. While early addition of sodium glucose cotransporter 2 inhibitors and mineralocorticoid receptor antagonists may be helpful, the value of the other therapeutics comes after decongestion is complete., Competing Interests: Declaration of competing interest The authors report no relationships that could be construed as a conflict of interest. The study was not supported by any funding sources., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
9. Proximal versus distal diuretics in congestive heart failure.
- Author
-
Nardone M, Sridhar VS, Yau K, Odutayo A, and Cherney DZI
- Subjects
- Humans, Sodium-Glucose Transporter 2 Inhibitors therapeutic use, Heart Failure drug therapy, Heart Failure etiology, Diuretics therapeutic use
- Abstract
Volume overload represents a hallmark clinical feature linked to the development and progression of heart failure (HF). Alleviating signs and symptoms of volume overload represents a foundational HF treatment target that is achieved using loop diuretics in the acute and chronic setting. Recent work has provided evidence to support guideline-directed medical therapies, such as sodium glucose cotransporter 2 (SGLT2) inhibitors and mineralocorticoid receptor (MR) antagonists, as important adjunct diuretics that may act synergistically when used with background loop diuretics in people with chronic HF. Furthermore, there is growing interest in understanding the role of SGLT2 inhibitors, carbonic anhydrase inhibitors, thiazide diuretics, and MR antagonists in treating volume overload in patients hospitalized for acute HF, particularly in the setting of loop diuretic resistance. Thus, the current review demonstrates that: (i) SGLT2 inhibitors and MR antagonists confer long-term cardioprotection in chronic HF patients but it is unclear whether natriuresis or diuresis represents the primary mechanisms for this benefit, (ii) SGLT2 inhibitors, carbonic anhydrase inhibitors, and thiazide diuretics increase natriuresis in the acute HF setting, but implications on long-term outcomes remain unclear and warrants further investigation, and (iii) a multi-nephron segment approach, using agents that act on distinct segments of the nephron, potentiate diuresis to alleviate signs and symptoms of volume overload in acute HF., (© The Author(s) 2024. Published by Oxford University Press on behalf of the ERA.)
- Published
- 2024
- Full Text
- View/download PDF
10. In brief: A new torsemide formulation (Soaanz) for edema.
- Subjects
- Humans, Diuretics administration & dosage, Diuretics therapeutic use, Diuretics adverse effects, Torsemide administration & dosage, Edema drug therapy
- Published
- 2024
- Full Text
- View/download PDF
11. Shared Medical Appointments in Heart Failure for Post Acute Care Follow-Up: A Randomized Controlled Trial.
- Author
-
Taveira TH, Cohen LB, Laforest SK, Oliver K, Parent M, Hearns R, Ball SL, Dev S, and Wu WC
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Health Status, Patient Care Team organization & administration, Treatment Outcome, Time Factors, Diuretics therapeutic use, Patient Discharge, Heart Failure therapy, Heart Failure mortality, Quality of Life, Shared Medical Appointments
- Abstract
Background: Shared medical appointments (SMAs) in heart failure (HF) are medical visits where several patients with HF meet with multidisciplinary providers at the same time for efficient and comprehensive care. It is unknown whether HF-SMAs can improve overall and cardiac health status for high-risk patients with HF discharged from acute care., Methods and Results: A 3-site, open-label, randomized-controlled-trial was conducted. Participants within 12 weeks of HF acute care (emergency-room/hospitalization) requiring intravenous diuretic therapy were randomized to receive either HF-SMA or usual HF clinical care (usual-care) on a 1:1 ratio. The HF-SMA team, which consisted of a nurse, nutritionist, psychologist, nurse practitioner and/or a clinical pharmacist, provided four 2-hour session HF-SMAs that met every other week for 8 weeks. Primary outcomes were the overall health status measured by European Quality of Life Visual Analog Scale and cardiac health status by Kansas City Cardiomyopathy Questionnaire, 180 days postrandomization. Of the 242 patients enrolled (HF-SMA n=117, usual-care n=125, mean age 69.3±9.4 years, 71.5% White patients, 94.6% male), 84% of participants completed the study (n=8 HF-SMA and n=9 usual-care patients died). After 180 days, both HF-SMA and usual-care participants had significant improvements from baseline in Kansas City Cardiomyopathy Questionnaire that were not statistically different. Only HF-SMA participants had significant improvements in European Quality of Life Visual Analog Scale (mean change = 7.2±15.8 in HF-SMA versus -0.4±19.0 points in usual-care, P < 0.001)., Conclusions: Both HF-SMA and usual-care in participants with HF achieved significant improvements in cardiac health status, but only a team approach through HF-SMA achieved significant improvements in overall health status. Future larger studies are needed to evaluate hospitalization and death outcomes., Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02481921.
- Published
- 2024
- Full Text
- View/download PDF
12. Prevalent and new use of common drugs for the incidence of community-acquired acute kidney injury: cohort and case-crossover study.
- Author
-
Kimachi M, Ikenoue T, and Fukuma S
- Subjects
- Humans, Female, Male, Incidence, Adult, Middle Aged, Cohort Studies, Diuretics adverse effects, Diuretics therapeutic use, Contrast Media adverse effects, Prevalence, Acute Kidney Injury epidemiology, Acute Kidney Injury chemically induced, Cross-Over Studies
- Abstract
Although community-acquired acute kidney injury (CA-AKI) represents a significant subset of all AKI incidence, evidence is limited due to the lack of comprehensive data prior to diagnosis. Here, we examined the risk of drug use for CA-AKI by using exhaustive pre-diagnostic prescription data. We included 78,754 working-age healthy individuals who underwent an annual health checkup program. We conducted a cohort study to assess the association between prevalent drug use and subsequent CA-AKI incidence using the Cox proportional hazard model. Subsequently, we conducted a case-crossover study to compare the new drug use in the case period directly before the CA-AKI incidence (- 3 to 0 months) with that in the control period far before the CA-AKI incidence (- 15 to - 12 months and - 9 to - 6 months) using the conditional Poisson regression model. The prevalent use of renin-angiotensin-aldosterone system (RAAS) inhibitors was associated with an increased CA-AKI incidence, but the new use was not. The new use of diuretics, anti-infectious drugs, and contrast medium was also associated with an increased CA-AKI incidence. These results suggest we need to pay attention for the incidence of AKI among the general population taking those common drugs., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
13. [Renal failure and drug-drug interactions].
- Author
-
Burkhardt H
- Subjects
- Humans, Aged, Diuretics adverse effects, Diuretics therapeutic use, Polypharmacy, Anticoagulants adverse effects, Anticoagulants therapeutic use, Drug Interactions, Renal Insufficiency chemically induced
- Abstract
Renal failure is common and comes with a steep increasing prevalence in older patients. It is a frequent aspect in multimorbidity and associated with polypharmacia. Based on available literature an overview is given concerning important drug-drug interactions and how to avoid or manage them. Among a large variety of possible interactions anticoagulation and diuretic therapy still represent the highest clinical relevance., (© 2024. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
14. Preferred diuretic therapy for primary hypertension: Chlorthalidone or hydrochlorothiazide?
- Author
-
Young TD
- Subjects
- Humans, Cardiovascular Diseases prevention & control, Cardiovascular Diseases drug therapy, Chlorthalidone administration & dosage, Chlorthalidone therapeutic use, Hydrochlorothiazide administration & dosage, Hydrochlorothiazide therapeutic use, Hypertension drug therapy, Diuretics administration & dosage, Diuretics therapeutic use, Antihypertensive Agents administration & dosage, Antihypertensive Agents therapeutic use
- Abstract
Abstract: Because of its greater reduction of major adverse cardiovascular events (MACE), chlorthalidone is recommended over hydrochlorothiazide as the preferred diuretic for patients with primary hypertension. However, hydrochlorothiazide is more commonly prescribed than chlorthalidone for this condition. This article reviews recent studies investigating the effectiveness of chlorthalidone and hydrochlorothiazide in reducing MACE, to help clinicians make an evidence-based informed decision on which diuretic to prescribe., (Copyright © 2024 American Academy of Physician Associates.)
- Published
- 2024
- Full Text
- View/download PDF
15. We Must Change Our Approach to Decongestion in Acute Heart Failure.
- Author
-
Howlett J and Ducharme A
- Subjects
- Humans, Acute Disease, Diuretics therapeutic use, Heart Failure drug therapy
- Abstract
Competing Interests: Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Published
- 2024
- Full Text
- View/download PDF
16. Rethinking diuretics for congestion in acute heart failure: insight from the STRONG-HF trial.
- Author
-
Caillard A, Čerlinskaitė-Bajorė K, and Mebazaa A
- Subjects
- Humans, Acute Disease, Randomized Controlled Trials as Topic, Treatment Outcome, Heart Failure drug therapy, Diuretics therapeutic use
- Published
- 2024
- Full Text
- View/download PDF
17. Optimizing diuretic treatment of patients with edema and nephrotic syndrome.
- Author
-
Hinrichs GR and Jensen BL
- Subjects
- Humans, Nephrotic Syndrome drug therapy, Edema drug therapy, Diuretics therapeutic use
- Published
- 2024
- Full Text
- View/download PDF
18. Using diuretic therapy in the critically ill patient.
- Author
-
Ostermann M, Awdishu L, and Legrand M
- Subjects
- Humans, Critical Illness therapy, Diuretics therapeutic use
- Published
- 2024
- Full Text
- View/download PDF
19. Torsemide is a More Appropriate Oral Loop Diuretic for Patients with Heart Failure: Commentary.
- Author
-
Coca SG
- Subjects
- Humans, Sodium Potassium Chloride Symporter Inhibitors administration & dosage, Sodium Potassium Chloride Symporter Inhibitors therapeutic use, Administration, Oral, Diuretics administration & dosage, Diuretics therapeutic use, Heart Failure drug therapy, Torsemide therapeutic use, Sulfonamides administration & dosage, Sulfonamides therapeutic use
- Published
- 2024
- Full Text
- View/download PDF
20. How a positive fluid balance develops in acute kidney injury: A binational, observational study.
- Author
-
White KC, Serpa-Neto A, Hurford R, Clement P, Laupland KB, Ostermann M, Sanderson B, Gatton M, and Bellomo R
- Subjects
- Humans, Retrospective Studies, Female, Male, Middle Aged, Aged, Hospital Mortality, Crystalloid Solutions administration & dosage, Crystalloid Solutions therapeutic use, Diuretics therapeutic use, Acute Kidney Injury therapy, Acute Kidney Injury physiopathology, Water-Electrolyte Balance, Fluid Therapy methods, Intensive Care Units, Critical Illness
- Abstract
Purpose: A positive fluid balance (FB) is associated with harm in intensive care unit (ICU) patients with acute kidney injury (AKI). We aimed to understand how a positive balance develops in such patients., Methods: Multinational, retrospective cohort study of critically ill patients with AKI not requiring renal replacement therapy., Results: AKI occurred at a median of two days after admission in 7894 (17.3%) patients. Cumulative FB became progressively positive, peaking on day three despite only 848 (10.7%) patients receiving fluid resuscitation in the ICU. In those three days, persistent crystalloid use (median:60.0 mL/h; IQR 28.9-89.2), nutritional intake (median:18.2 mL/h; IQR 0.0-45.9) and limited urine output (UO) (median:70.8 mL/h; IQR 49.0-96.7) contributed to a positive FB. Although UO increased each day, it failed to match input, with only 797 (10.1%) patients receiving diuretics in ICU. After adjustment, a positive FB four days after AKI diagnosis was associated with an increased risk of hospital mortality (OR 1.12;95% confidence intervals 1.05-1.19;p-value <0.001)., Conclusion: Among ICU patients with AKI, cumulative FB increased after diagnosis and was associated with an increased risk of mortality. Continued crystalloid administration, increased nutritional intake, limited UO, and minimal use of diuretics all contributed to positive FB., Key Points: Question How does a positive fluid balance develop in critically ill patients with acute kidney injury? Findings Cumulative FB increased after AKI diagnosis and was secondary to persistent crystalloid fluid administration, increasing nutritional fluid intake, and insufficient urine output. Despite the absence of resuscitation fluid and an increasing cumulative FB, there was persistently low diuretics use, ongoing crystalloid use, and a progressive escalation of nutritional fluid therapy. Meaning Current management results in fluid accumulation after diagnosis of AKI, as a result of ongoing crystalloid administration, increasing nutritional fluid, limited urine output and minimal diuretic use., Competing Interests: Declaration of competing interest The authors have no conflicts of interest to declare., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
21. Contemporary Decongestion Strategies in Patients Hospitalized for Heart Failure: A National Community-Based Cohort Study.
- Author
-
Zheng J, Ambrosy AP, Bhatt AS, Collins SP, Flint KM, Fonarow GC, Fudim M, Greene SJ, Lala A, Testani JM, Varshney AS, Wi RSK, and Sandhu AT
- Subjects
- Humans, Female, Male, Aged, United States epidemiology, Middle Aged, Aged, 80 and over, Cohort Studies, Heart Failure drug therapy, Heart Failure physiopathology, Diuretics therapeutic use, Diuretics administration & dosage, Hospitalization statistics & numerical data, Weight Loss
- Abstract
Background: Heart failure (HF) is a leading cause of hospitalization in the United States. Decongestion remains a central goal of inpatient management, but contemporary decongestion practices and associated weight loss have not been well characterized nationally., Objectives: This study aimed to describe contemporary inpatient diuretic practices and clinical predictors of weight loss in patients hospitalized for HF., Methods: The authors identified HF hospitalizations from 2015 to 2022 in a U.S. national database aggregating deidentified patient-level electronic health record data across 31 geographically diverse community-based health systems. The authors report patient characteristics and inpatient weight change as a primary indicator of decongestion. Predictors of weight loss were evaluated using multivariable models. Temporal trends in inpatient diuretic practices, including augmented diuresis strategies such as adjunctive thiazides and continuous diuretic infusions, were assessed., Results: The study cohort included 262,673 HF admissions across 165,482 unique patients. The median inpatient weight loss was 5.3 pounds (Q1-Q3: 0.0-12.8 pounds) or 2.4 kg (Q1-Q3: 0.0-5.8 kg). Discharge weight was higher than admission weight in 20% of encounters. An increase of ≥0.3 mg/dL in serum creatinine from admission to inpatient peak occurred in >30% of hospitalizations and was associated with less weight loss. Adjunctive diuretic agents were utilized in <20% of encounters but were associated with greater weight loss., Conclusions: In a large-scale U.S. community-based cohort study of HF hospitalizations, estimated weight loss from inpatient decongestion remains highly variable, with weight gain observed across many admissions. Augmented diuresis strategies were infrequently used. Comparative effectiveness trials are needed to establish optimal strategies for inpatient decongestion for acute HF., Competing Interests: Funding Support and Author Disclosures Dr Zheng has served as a consultant for Reprieve Cardiovascular. Dr Ambrosy has received relevant research support through grants to his institution from the National Heart, Lung, and Blood Institute (number K23HL150159), the American Heart Association (Second Century Early Faculty Independence Award), The Permanente Medical Group, Northern California Community Benefits Programs, Garfield Memorial Fund, Abbott Laboratories, Amarin Pharma, Edwards Lifesciences LLC, Esperion Therapeutics, and Novartis. Dr Bhatt has received relevant research support through grants to his institution from the National Heart, Lung, and Blood Institute, National Institute on Aging, the Centers for Disease Control and Prevention, and the American College of Cardiology Foundation; and previously received consulting fees from Sanofi Pasteur. Dr Collins has received research support from the National Institutes of Health, Patient-Centered Outcomes Research Institute, Department of Defense, and Beckman Coulter; and consulting fees from Abbott, Redesign Health, and Reprieve Cardiovascular, Inc. Dr Flint has received relevant grant funding from Abbott. Dr Fonarow has served as a consultant for Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Eli Lilly, Johnson and Johnson, Medtronic, Merck, Novartis, and Pfizer. Dr Greene has received research support from the Duke University Department of Medicine Chair’s Research Award, American Heart Association (number 929502), Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer, and Sanofi; served on the advisory board or as a consultant for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim/Lilly, Bristol Myers Squibb, Corteria, CSL Vifor, Cytokinetics, Lexicon, Merck, Roche Diagnostics, Sanofi, scPharmaceuticals, Tricog Health, and Urovant Pharmaceuticals; and received speaker fees from Boehringer Ingelheim, Cytokinetics, Lexicon, and Roche Diagnostics. Dr Varshney has received consulting fees from Broadview Ventures. Dr Sandhu has received relevant research support from the National Heart, Lung, Blood Institute (number 1K23HL151672) and the American Heart Association; and served as a consultant for Reprieve Cardiovascular, Lexicon Pharmaceuticals, and Cleerly. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
22. Utility of F-15 diuretic MAG3 renography in assessment of paediatric hydronephrosis.
- Author
-
Roy C, Godse A, Lall A, Peace R, and Gopal M
- Subjects
- Humans, Retrospective Studies, Child, Male, Female, Child, Preschool, Infant, Diuretics therapeutic use, Furosemide administration & dosage, Adolescent, Radiopharmaceuticals, Ureteral Obstruction diagnostic imaging, Ureteral Obstruction surgery, Hydronephrosis diagnostic imaging, Hydronephrosis diagnosis, Radioisotope Renography methods, Technetium Tc 99m Mertiatide
- Abstract
Introduction: Diuretic renography is crucial in evaluation of paediatric hydronephrosis. Furosemide is conventionally given 15-20 min after radiolabelled tracer (F+15/F+20 protocol), however this is equivocal in around 15% of patients. Giving furosemide 15 min prior to tracer (F-15 MAG3 protocol) has been suggested as an additional tool in the investigation of patients with suspected upper urinary tract obstruction. However, the role of this method in assessment and management of paediatric hydronephrosis is not widely reported., Objective: To investigate utility of F-15 renograms in children with hydronephrosis being assessed for Pelvi-Ureteric Junction Obstruction (PUJO)., Study Design: Retrospective review of patients <16 years old undergoing F-15 MAG3 renogram between 2018 and 2021 in our tertiary paediatric surgical centre. Data collected included patient demographics, mode of presentation, investigations, management and outcomes., Results: Eighteen patients were included. Median age at F-15 renogram was 7.3 years. Eleven patients presented with antenatal hydronephrosis, 5 with symptoms in childhood and 2 with incidental hydronephrosis on trauma imaging. Fourteen patients were symptomatic. Ten had a prior non-obstructed F+20 renogram but persisting symptoms suggestive of PUJO. Seven had previous equivocal F+20 renograms. One symptomatic patient directly underwent an F-15 renogram. A conclusive result was obtained in 16/18 (89%); 11 patients had obstructed curves and 5 non-obstructed. Two asymptomatic patients' scans were inconclusive. All symptomatic patients had conclusive scans. Of 11 patients with an obstructed F-15, 9 have undergone pyeloplasty to date. All have had post-operative resolution in symptoms and static or improved post-operative ultrasound. One patient with an inconclusive scan underwent pyeloplasty due to persisting hydronephrosis and parent preference. Three patients with non-obstructed F-15 renograms have been discharged. One symptomatic patient with a non-obstructive F-15 had a ureteric stent inserted due to persistent flank pain; 1 continues under surveillance., Discussion: It is known that conventional F+20 MAG3 renograms can give equivocal results. Published experience suggests that F-15 renograms are conclusive in the majority of patients. Routine primary use is, however, discouraged as they can 'over diagnose' obstruction and limit the study of tracer transit under physiological flow rates. This study indicates that the F-15 renogram is a useful adjunct in the assessment of patients with symptoms suggestive of PUJO who have previously had an equivocal or a non-obstructed F+20 renogram., Conclusion: F-15 renogram was conclusive in 89% of patients. We recommend using F-15 renograms to aid surgical decision-making in children with equivocal F+20 renograms, especially in the presence of symptoms., Competing Interests: Conflict of interest None., (Copyright © 2024 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
23. Diuretics in neonatology: a narrative review and update.
- Author
-
Iacobelli S
- Subjects
- Humans, Infant, Newborn, Infant, Premature, Ductus Arteriosus, Patent drug therapy, Furosemide therapeutic use, Neonatology, Hyaline Membrane Disease drug therapy, Transient Tachypnea of the Newborn drug therapy, Infant, Very Low Birth Weight, Sodium Potassium Chloride Symporter Inhibitors therapeutic use, Infant, Newborn, Diseases drug therapy, Intensive Care Units, Neonatal, Off-Label Use, Diuretics therapeutic use
- Abstract
Diuretics are medications that promote the excretion of water and electrolytes. They are primarily used in the management and treatment of states of inappropriate salt and water retention. Diuretics represent one of the most common classes of drugs administered to sick neonates, the more so in very low birth weight infants. Diuretic drugs, especially loop diuretics, are often administered in the neonatal intensive care unit as off-label medications. This is the case for a variety of clinical situations, in which an increase in sodium excretion is not the primary goal of treatment (transitory tachypnoea of the newborn at term, hyaline membrane disease, patent ductus arteriosus of preterm infants). Thiazides and furosemide are widely used to treat preterm infants with oxygen-dependent chronic lung disease, despite a lack of data on beneficial effect of long-term therapy on pulmonary function or clinical outcome. This article reviews the mechanism of action, indications, administration, posology, adverse effects and contraindications of diuretics in newborn infants. Based on the most recent information available in the literature, we will discuss data supporting (or questioning) the use of diuretic in specific neonatal diseases. Research priorities over this issue will be briefly presented.
- Published
- 2024
- Full Text
- View/download PDF
24. Thiazides for the prevention of kidney stone recurrence: are they really effective?
- Author
-
Buso H, Butera E, Tramontano D, and Bandini G
- Subjects
- Humans, Recurrence, Thiazoles therapeutic use, Secondary Prevention methods, Diuretics therapeutic use, Kidney Calculi prevention & control
- Published
- 2024
- Full Text
- View/download PDF
25. Combinational Diuretics in Heart Failure.
- Author
-
Trullàs JC, Casado J, Cobo-Marcos M, Formiga F, Morales-Rull JL, Núñez J, and Manzano L
- Subjects
- Humans, Sodium Potassium Chloride Symporter Inhibitors therapeutic use, Sodium Potassium Chloride Symporter Inhibitors administration & dosage, Heart Failure drug therapy, Heart Failure physiopathology, Drug Therapy, Combination, Diuretics therapeutic use, Diuretics administration & dosage
- Abstract
Purpose of Review: Diuretics are the cornerstone therapy for acute heart failure (HF) and congestion. Patients chronically exposed to loop diuretics may develop diuretic resistance as a consequence of nephron remodelling, and the combination of diuretics will be necessary to improve diuretic response and achieve decongestion. This review integrates data from recent research and offers a practical approach to current pharmacologic therapies to manage congestion in HF with a focus on combinational therapy., Recent Findings: Until recently, combined diuretic treatment was based on observational studies and expert opinion. Recent evidence from clinical trials has shown that combined diuretic treatment can be started earlier without escalating the doses of loop diuretics with an adequate safety profile. Diuretic combination is a promising strategy for overcoming diuretic resistance in HF. Further studies aiming to get more insights into the pathophysiology of diuretic resistance and large clinical trials confirming the safety and efficacy over standard diuretics regimens are warranted., (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
26. Non-steroidal anti-inflammatory drugs, renin-angiotensin system blockade or diuretics and risk of acute kidney injury: A case-crossover study.
- Author
-
Weng SE, Hsu WT, Hsiao FY, and Lee CM
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Renin-Angiotensin System drug effects, Taiwan epidemiology, Risk Factors, Drug Therapy, Combination adverse effects, Angiotensin-Converting Enzyme Inhibitors adverse effects, Case-Control Studies, Aged, 80 and over, Acute Kidney Injury chemically induced, Acute Kidney Injury epidemiology, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Cross-Over Studies, Diuretics adverse effects, Diuretics therapeutic use
- Abstract
Background: Aging-related physiological changes, such as decline in renal function, not only exacerbates pre-existing comorbidities but also escalate the susceptibility to adverse events. Previous studies have shown that non-steroidal anti-inflammatory drugs (NSAIDs) are associated with an increased risk of acute kidney injury (AKI), and the concomitant use of renin-angiotensin system blockade or diuretics may further potentiate the risk. However, studies evaluating the risk of AKI associated with NSAIDs (including routes, concomitant use of different NSAIDs, categories (traditional NSAIDs or COX-2 inhibitors), and cumulative doses of NSAIDs) are limited, particularly the risk of AKI associated with the dual or triple combination of NSAIDs with renin-angiotensin system blockade (RAS blockades) and/or diuretics., Methods: A case-crossover study utilized two sets of longitudinal data from Taiwan's National Health Insurance Research Database (NHIRD). Newly admitted patients with a primary AKI diagnosis were included, with the index date defined as the first admission date. The 1-7 days and 181-187 days prior to the index date served as the case and control periods. Exposure to NSAIDs and co-exposures of RAS blockade and/or diuretics were assessed in both periods. Multivariable conditional logistic regression models, adjusting for potential confounders, estimated adjusted odds ratios (aORs) and 95 % confidence intervals (CIs) for AKI associated with NSAIDs, dual, or triple combinations. Sensitivity analyses explored result robustness by varying case and control period lengths., Results: The study included 1,284 newly diagnosed AKI patients. NSAIDs showed a 3.55-fold increased risk of AKI (aOR: 3.55; 95 % CI 2.70-4.65), with similar risks for traditional NSAIDs and COX-2 inhibitors. Use of multiple NSAIDs, parenteral dosage forms, and higher cumulative doses increased AKI risk. Dual combination with either RAS blockade or diuretics resulted in a 2.90-fold (aOR: 2.90; 95 %CI 1.47-5.70) and 12.68-fold (aOR: 12.68; 95 %CI 6.15-26.12) risk, respectively. The highest risk occurred with triple combination (aOR: 29.22; 95 %CI 12.82-66.64)., Conclusions: NSAIDs, including both non-selective NSAIDs and COX2 inhibitors, elevate the risk of AKI. Increased AKI risk is linked to using multiple NSAIDs, the parenteral dosage form, and higher cumulative doses. Dual combination of RAS blockade with NSAIDs or diuretics with NSAIDs, as well as triple therapy, heightens the risk, with the latter associated with the highest risk of AKI., Competing Interests: Declaration of competing interest The authors declare no conflicts of interest., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
27. Diuresis Efficacy in Ambulatory Congested Heart Failure Patients: Intrapatient Comparison of 3 Diuretic Regimens (DEA-HF).
- Author
-
Abbo AR, Gruber A, Volis I, Aronson D, Girerd N, Lund Kristensen S, Zukermann R, Alberkant N, Sitnitsky E, Kruger A, Khasis P, Bravo E, Elad B, Helmer Levin L, and Caspi O
- Subjects
- Humans, Male, Female, Aged, Prospective Studies, Middle Aged, Drug Therapy, Combination, Diuresis drug effects, Treatment Outcome, Heart Failure drug therapy, Heart Failure physiopathology, Furosemide administration & dosage, Furosemide therapeutic use, Diuretics administration & dosage, Diuretics therapeutic use, Acetazolamide administration & dosage, Acetazolamide therapeutic use, Metolazone administration & dosage, Cross-Over Studies
- Abstract
Background: Limited evidence exists regarding efficacy and safety of diuretic regimens in ambulatory, congestion-refractory, chronic heart failure (CHF) patients., Objectives: The authors sought to compare the potency and safety of commonly used diuretic regimens in CHF patients., Methods: A prospective, randomized, open-label, crossover study conducted in NYHA functional class II to IV CHF patients, treated in an ambulatory day-care unit. Each patient received 3 different diuretic regimens: intravenous (IV) furosemide 250 mg; IV furosemide 250 mg plus oral metolazone 5 mg; and IV furosemide 250 mg plus IV acetazolamide 500 mg. Treatments were administered once a week, in 1 of 6 randomized sequences. The primary endpoint was total sodium excretion, and the secondary was total urinary volume excreted, both measured for 6 hours post-treatment initiation., Results: A total of 42 patients were recruited. Administration of furosemide plus metolazone resulted in the highest weight of sodium excreted, 4,691 mg (95% CI: 4,153-5,229 mg) compared with furosemide alone, 3,835 mg (95% CI: 3,279-4,392 mg; P = 0.015) and to furosemide plus acetazolamide 3,584 mg (95% CI: 3,020-4,148 mg; P = 0.001). Furosemide plus metolazone resulted in 1.84 L of urine (95% CI: 1.63-2.05 L), compared with 1.58 L (95% CI: 1.37-1.8); P = 0.039 collected following administration of furosemide plus acetazolamide and 1.71 L (95% CI: 1.49-1.93 L) following furosemide alone. The incidence of worsening renal function was significantly higher when adding metolazone (39%) to furosemide compared with furosemide alone (16%) and to furosemide plus acetazolamide (2.6%) (P < 0.001)., Conclusions: In ambulatory CHF patients, furosemide plus metolazone resulted in a significantly higher natriuresis compared with IV furosemide alone or furosemide plus acetazolamide., Competing Interests: Funding Support and Author Disclosures Dr Abbo has been a consultant for Edwards Life Sciences; and has received speaker honoraria from Boehringer Ingelheim. Dr Kristensen has been a consultant for Bayer; and has received speaker honoraria from AstraZeneca. Dr Caspi has received speaker honoraria from AstraZeneca, Novo Nordisk, and Pfizer; and has received consultancy honoraria from Vectorious medical technologies. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
28. A review regarding the article 'Basal natriuresis as a predictor of diuretic resistance and clinical evolution in acute heart failure'.
- Author
-
Li K, Shi R, and Luo L
- Subjects
- Humans, Acute Disease, Diuretics therapeutic use, Prognosis, Sodium Potassium Chloride Symporter Inhibitors therapeutic use, Sodium Potassium Chloride Symporter Inhibitors pharmacology, Heart Failure physiopathology, Heart Failure drug therapy, Heart Failure diagnosis, Natriuresis drug effects, Natriuresis physiology, Drug Resistance
- Abstract
Acute heart failure (AHF) is characterized by the emergence or intensification of symptoms and signs indicative of congestion or systemic hypoperfusion, stemming from an underlying structural or functional cardiac disorder. Intravenous loop diuretics play a pivotal role in achieving effective decongestion and ensuring clinical stability; the efficacy of these medications is crucial for determining the patient's hospital course and early outpatient progression. Individuals who exhibit a suboptimal response to diuretics or develop diuretic resistance (DR) are at an elevated risk for cardiovascular mortality and readmission due to AHF. However, there is a lack of standardized definition and diagnostic criteria for DR. Early identification of patients with DR is critical, as they may benefit from more aggressive decongestion strategies to mitigate this resistance. Natriuresis, the excretion of sodium in urine, serves as a direct measure of a diuretic's effectiveness. Low levels of natriuresis have been linked to poorer outcomes. Several studies have underscored the prognostic significance of natriuresis across various heart failure scenarios. However, the relationship between natriuresis and in-hospital DR has not been extensively studied. Observational research has indicated that inadequate natriuresis following the administration of loop diuretics correlates with a diminished diuretic response and an increased likelihood of mortality and heart failure rehospitalization. Further investigation is warranted to assess the predictive value of basal natriuresis concerning DR, in-hospital outcomes, and early outpatient cardiovascular events. This would help in identifying patients who are likely to respond poorly to diuretic therapy and may require alternative or more intensive treatment approaches., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
29. Basal natriuresis as a predictor of diuretic resistance and clinical evolution in acute heart failure.
- Author
-
Scatularo CE, Battioni L, Guazzone A, Esperón G, Corsico L, and Grancelli HO
- Subjects
- Humans, Female, Male, Prospective Studies, Aged, Acute Disease, Aged, 80 and over, Middle Aged, Hospital Mortality trends, Heart Failure physiopathology, Heart Failure drug therapy, Natriuresis drug effects, Natriuresis physiology, Diuretics therapeutic use, Furosemide therapeutic use, Furosemide administration & dosage, Drug Resistance
- Abstract
Background: Some clinical guidelines recommend serial measurement of natriuresis to detect diuretic resistance (DR) in acute heart failure (AHF) patients, but it adds complexity to the management., Objectives: To correlate a single measurement of basal natriuresis (BN) on admission with the development of DR and clinical evolution in AHF hospitalized patients., Methods: Prospective and multicenter study included AHF hospitalized patients, without shock or creatinine >2.5mg%. Patients received 40mg of intravenous furosemide on admission, then BN was measured, and diuretic treatment was guided by protocol. BN was considered low if <70 meq/L. DR was defined as the need of furosemide >240mg/day, tubular blockade (TB), hypertonic saline solution (HSS) or renal replacement therapy (RRT). In-hospital cardiovascular (CV) mortality, CV mortality and AHF readmissions at 60-day post-discharge were evaluated., Results: 157 patients were included. BN was low in 22%. DR was development in 19% (12.7% furosemide >240mg/day, 8% TB, 4% RRT). Low NB was associated with DR (44% vs 12%; p 0.0001), persistence of congestion (26.5% vs 11.4%; p 0.05), furosemide >240 mg/day (29% vs 8%; p 0.003), higher cumulative furosemide dose at 72 hours (220 vs 160mg; p 0.0001), TB (20.6 vs 4.9%; p 0.008), RRT (11.8 vs 1.6%; p 0.02), worsening of AHF (27% vs 9%; p 0.01), inotropes use (21% vs 7%; p 0.48), respiratory assistance (12% vs 2%; p 0.02) and a higher in-hospital CV mortality (12% vs 4%; p 0.1). No association was demonstrated with post-discharge endpoints., Conclusions: In AHF patients, low BN was associated with DR, persistent congestion, need for aggressive decongestion strategies, and worse in-hospital evolution., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
30. Estimating the effect of diuretics and inhaled corticosteroids for evolving bronchopulmonary dysplasia in preterm infants.
- Author
-
Slaughter JL, Klebanoff MA, and Hade EM
- Subjects
- Humans, Infant, Newborn, Female, Administration, Inhalation, Male, Gestational Age, Infant, Premature, Intensive Care Units, Neonatal statistics & numerical data, Respiration, Artificial statistics & numerical data, Infant, Bronchopulmonary Dysplasia drug therapy, Bronchopulmonary Dysplasia mortality, Diuretics therapeutic use, Adrenal Cortex Hormones therapeutic use, Adrenal Cortex Hormones administration & dosage, Infant, Extremely Premature
- Abstract
Background: Off-label treatment of extremely preterm infants with diuretics and inhaled corticosteroids (ICS) for evolving bronchopulmonary dysplasia (BPD) is common. Their effectiveness in reducing mortality or BPD severity, and optimal treatment timing, are unclear., Objectives: To determine whether diuretic treatment or ICS administration for infants with early evolving (between 10-27 days postnatal) and progressively evolving (28th-day-36th-week postnatal) BPD are independently associated with reduced mortality and moderate or severe BPD at 36-weeks postmenstrual age (PMA)., Methods: We examined neonates born before 28 weeks' gestation and admitted to neonatal intensive care units on postnatal Day 0 between 2006 and 2016 using data collected during routine care recorded within the Paediatric Health Information System (PHIS). An early evolving BPD cohort consisted of infants treated with oxygen, positive pressure or mechanical ventilation at 10 days postnatal. The progressively evolving BPD cohort consisted of infants treated with these modalities at 28 days. In new users, we evaluated the effect of diuretic and ICS treatment on mortality or BPD severity at 36 weeks PMA, adjusting for time-dependent confounding by respiratory status using marginal structural models., Results: Early evolving BPD was present in 10,135 patients; progressively evolving BPD in 11,728. New diuretic exposure during early evolving BPD (adjusted risk ratio [aRR] 0.77, 95% confidence interval [CI] 0.65, 0.93) was associated with decreased mortality or moderate/severe BPD risk. New diuretics (aRR 0.86, 95% CI 0.75, 0.99) during progressively evolving BPD between 28-days-36-weeks PMA were less strongly associated with mortality or moderate/severe BPD reduction. There was no strong association for ICS in patients with early evolving (aRR: 1.40; 95% CI: 0.79, 2.51) or progressively evolving BPD (aRR 1.16, 95% CI 0.95, 1.49)., Conclusion: Diuretics, but not ICS, for evolving BPD were associated with mortality and BPD risk reduction., (© 2024 The Authors. Paediatric and Perinatal Epidemiology published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
31. Amiloride versus furosemide for the treatment of edema in patients with nephrotic syndrome: A pilot study (AMILOR).
- Author
-
Schork A, Vogel E, Bohnert BN, Essigke D, Wörn M, Fischer I, Heyne N, Birkenfeld AL, and Artunc F
- Subjects
- Humans, Pilot Projects, Male, Female, Middle Aged, Adult, Epithelial Sodium Channel Blockers therapeutic use, Aged, Amiloride therapeutic use, Furosemide therapeutic use, Nephrotic Syndrome drug therapy, Nephrotic Syndrome complications, Diuretics therapeutic use, Edema drug therapy
- Abstract
Aim: In rodent models of nephrotic syndrome (NS), edema formation was prevented by blockade of the epithelial sodium channel ENaC with amiloride. However, apart from case reports, there is no evidence favoring ENaC blockade in patients with NS., Methods: The monocentric randomized controlled AMILOR study investigated the antiedematous effect of amiloride (starting dose 5 mg/day, max. 15 mg/day) in comparison to standard therapy with the loop diuretic furosemide (40 mg/day, max. 120 mg/day) over 16 days. Overhydration (OH) was measured by bioimpedance spectroscopy (BCM, Fresenius). Depending on the OH response, diuretic dose was adjusted on days 2, 5, 8 and 12, and if necessary, hydrochlorothiazide (HCT) was added from d8 (12.5 mg/day, max. 25 mg/day). The primary endpoint was the decrease in OH on d8. The study was terminated prematurely due to insufficient recruitment and a low statistical power due to a low actual effect size., Results: Median baseline OH was +26.4 (interquartile range 15.5-35.1)% extracellular water (ECW) in the amiloride arm and + 27.9 (24.1-29.4)% ECW in the furosemide arm and decreased by 1.95 (0.80-6.40) and 5.15 (0.90-8.30)% ECW after 8 days, respectively, and by 10.10 (1.30-14.40) and 7.40 (2.80-10.10)% ECW after 16 days, respectively. OH decrease on d8 and d16 was not significantly different between both arms., Conclusion: The AMILOR study is the first randomized controlled pilot study suggesting a similar antiedematous effect as furosemide. Further studies are required to better define the role of amiloride in NS (EudraCT 2019-002607-18)., (© 2024 The Author(s). Acta Physiologica published by John Wiley & Sons Ltd on behalf of Scandinavian Physiological Society.)
- Published
- 2024
- Full Text
- View/download PDF
32. Torsemide versus Furosemide in the Treatment of Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Author
-
Teixeira L, Felix N, Navalha DDP, Ferreira R, Clemente MRC, Madeira T, Nogueira A, and Tramujas L
- Subjects
- Humans, Treatment Outcome, Diuretics therapeutic use, Furosemide therapeutic use, Heart Failure drug therapy, Heart Failure mortality, Torsemide therapeutic use, Randomized Controlled Trials as Topic, Hospitalization statistics & numerical data
- Abstract
Furosemide is the most used diuretic for volume overload symptoms in patients with heart failure (HF). Recent data suggested that torsemide may be superior to furosemide in this setting. However, whether this translates into better clinical outcomes in this population remains unclear. To assess whether torsemide is superior to furosemide in the setting of HF. We performed a systematic review and meta-analysis of RCTs comparing the efficacy of torsemide versus furosemide in patients with HF. PubMed, Embase, and Web of Science were searched for eligible trials. Outcomes of interest were all-cause hospitalizations, hospitalizations for HF (HHF), hospitalizations for all cardiovascular causes, all-cause mortality, and NYHA class improvement. Echocardiographic parameters were also assessed. We applied a random-effects model to calculate risk ratios (RR) and mean differences (MD) with 95% confidence intervals (CI) and a 0.05 level of significance. 12 RCTs were included, comprising 4,115 patients. Torsemide significantly reduced HHF (RR 0.60; 95% CI, 0.43-0.83; p=0.002; I2=0%), hospitalization for cardiovascular causes (RR 0.72; 95% CI, 0.60-0.88; p=0.0009; I2=0%), and improved LVEF (MD 4.51%; 95% CI, 2.94 to 6.07; p<0.0001; I2=0%) compared with furosemide. There was no significant difference in all-cause hospitalizations (RR 0.93; 95% CI, 0.86-1.00; p=0.04; I2=0%), all-cause mortality (RR 0.98; 95% CI, 0.87-1.10; p=0.73; I2=0%), NYHA class improvement (RR 1.25; 95% CI, 0.92-1.68; p=0.15; I2=0%), or NYHA class change (MD -0.04; 95% CI, -0.24 to 0.16; p=0.70; I2=15%) between groups. Torsemide significantly reduced hospitalizations for HF and cardiovascular causes, also improving LVEF.
- Published
- 2024
- Full Text
- View/download PDF
33. Antihypertensives Might Explain Some Older Adults' New Eczema Diagnoses.
- Author
-
Bock A
- Subjects
- Aged, Humans, Hypertension drug therapy, Middle Aged, Diuretics adverse effects, Diuretics therapeutic use, Calcium Channel Blockers adverse effects, Calcium Channel Blockers therapeutic use, Antihypertensive Agents adverse effects, Antihypertensive Agents therapeutic use, Eczema chemically induced, Eczema etiology
- Published
- 2024
- Full Text
- View/download PDF
34. Cost-effectiveness of single-pill and separate-pill administration of antihypertensive triple combination therapy: a population-based microsimulation study.
- Author
-
Morabito G, Gregorio C, Ieva F, Barbati G, Mancia G, Corrao G, and Rea F
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Italy, Adult, Drug Combinations, Angiotensin-Converting Enzyme Inhibitors economics, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Angiotensin-Converting Enzyme Inhibitors administration & dosage, Calcium Channel Blockers economics, Calcium Channel Blockers therapeutic use, Calcium Channel Blockers administration & dosage, Markov Chains, Drug Therapy, Combination, Aged, 80 and over, Computer Simulation, Diuretics administration & dosage, Diuretics economics, Diuretics therapeutic use, Cost-Benefit Analysis, Antihypertensive Agents economics, Antihypertensive Agents administration & dosage, Antihypertensive Agents therapeutic use, Hypertension drug therapy
- Abstract
Background: Single-pill combination (SPC) of three antihypertensive drugs has been shown to improve adherence to therapy compared with free combinations, but little is known about its long-term costs and health consequences. This study aimed to evaluate the lifetime cost-effectiveness profile of a three-drug SPC of an angiotensin-converting enzyme inhibitor, a calcium-channel blocker, and a diuretic vs the corresponding two-pill administration (a two-drug SPC plus a third drug separately) from the Italian payer perspective., Methods: A cost-effectiveness analysis was conducted using multi-state semi-Markov modeling and microsimulation. Using the healthcare utilization database of the Lombardy Region (Italy), 30,172 and 65,817 patients aged ≥ 40 years who initiated SPC and two-pill combination, respectively, between 2015 and 2018 were identified. The observation period extended from the date of the first drug dispensation until death, emigration, or December 31, 2019. Disease and cost models were parametrized using the study cohort, and a lifetime microsimulation was applied to project costs and life expectancy for the compared strategies, assigning each of them to each cohort member. Costs and life-years gained were discounted by 3%. Probabilistic sensitivity analysis with 1,000 samples was performed to address parameter uncertainty., Results: Compared with the two-pill combination, the SPC increased life expectancy by 0.86 years (95% confidence interval [CI] 0.61-1.14), with a mean cost differential of -€12 (95% CI -9,719-8,131), making it the dominant strategy (ICER = -14, 95% CI -€15,871-€7,113). The cost reduction associated with the SPC was primarily driven by savings in hospitalization costs, amounting to €1,850 (95% CI 17-7,813) and €2,027 (95% CI 19-8,603) for patients treated with the SPC and two-pill combination, respectively. Conversely, drug costs were higher for the SPC (€3,848, 95% CI 574-10,640 vs. €3,710, 95% CI 263-11,955). The cost-effectiveness profile did not significantly change according to age, sex, and clinical status., Conclusions: The SPC was projected to be cost-effective compared with the two-pill combination at almost all reasonable willingness-to-pay thresholds. As it is currently prescribed to only a few patients, the widespread use of this strategy could result in benefits for both patients and the healthcare system., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
35. FIRE Stones: impact of forced diuresis on the residual fragment rate after flexible ureteroscopy for destruction of kidney stones with laser-protocol for a randomized controlled two-parallel group multicenter trial with blinding evaluation.
- Author
-
Letouche ML, Giraudeau B, Agier MS, and Bruyere F
- Subjects
- Humans, Treatment Outcome, Diuretics therapeutic use, Time Factors, Lithotripsy, Laser methods, Lithotripsy, Laser adverse effects, France, Diuresis drug effects, Ureteroscopes, Furosemide administration & dosage, Furosemide therapeutic use, Kidney Calculi surgery, Kidney Calculi therapy, Ureteroscopy methods, Ureteroscopy adverse effects, Randomized Controlled Trials as Topic, Multicenter Studies as Topic
- Abstract
Background: Lithiasis is a common and recurrent disease. Flexible ureteroscopy (fURS) is the cornerstone of laser treatment of kidney stones. Kidney stones destruction requires its laser pulverization into small fragments in order to remove them through the ureter or improve their spontaneous expulsion along the urinary tract. However, most of the time, all the micro-fragments and dust created cannot be extracted using our surgical tools and may stay intra-renally at the end of the procedure. Adjuvant treatments (such as forced diuresis, inversion or mechanical pressure) were previously described to improve the expulsion of stone fragments after extra-corporeal shock wave lithotripsy. Nevertheless, the impact of adjuvant treatment after fURS remains unclear and mainly theoretical., Objective: The primary objective is to show that the injection of 40 mg of furosemide in slow intravenous during 10 min, after the procedure, increases the stone-free rate 3 months after a fURS for destruction of kidney stones with laser., Methods/design: The study will be a two-parallel group randomized, controlled, multicentric trial with a blinding evaluation. Nine French departments of urology will participate. Patients will be randomized in 2 groups: the experimental group (injection of 40 mg of furosemide at the end of the surgery) and a control one (usual care). Patients will be followed up for 3 months (± 2 weeks) after the surgery. Then, we will perform a low dose abdomino-pelvic CT scan. The primary outcome is the stone-free rate at 3 months. A centralized review of the images will be performed by two specialized radiologists, in a blind and crossed way to allow a homogenization of the results. The secondary outcomes will include the rate of early post-operative urinary tract infection (UTI), the evaluation of post-operative pain, and the safety of the use of furosemide in patients treated by fURS for renal stone laser destruction. As secondary objectives, it is also planned to look at the effect of the prescription of an alpha-blocker as usual treatment on stone-free rate and to assess the agreement between the imaging analysis of the urologist and the specialized radiologist., Discussion: Lithiasis is a public health problem. It affects about 10% of the general population. This prevalence is increasing (multiplied by 3 in 40 years), partly due to changes in the population's eating habits over the years. The lithiasis patient is a patient with a chronic disease requiring annual follow-up and who may suffer from multiple recurrences, with a recurrence rate at 5 years of 50%. Recurrences are partly due to residual fragments left in the kidneys at the end of the operation. Other risk factors for recurrence include dietary hygiene and the presence of an associated metabolic disease. The metabolic blood and urine tests recommended by the Association Française d'Urologie (AFU) can be used to manage these last two problems. As far as residual fragments are concerned, their presence leads to an early recurrence of stones because they form the bed for a new aggregation of crystals in the kidneys. Being able to reduce the rate of residual fragments in patients with the use of furosemide at the end of the intervention therefore seems essential in the management of recurrences in our patients. This will also improve our patients' quality of life. Indeed, lithiasis disease leads to chronic pain associated with acute pain that motivates consultations to the emergency for specialized management. This study is the first to evaluate the impact of forced diuresis with the use of furosemide on the stone-free rate after a fURS for destruction of kidney stone with laser., Trial Registration: ClinicalTrials.gov Identifier: NCT05916963 , first received: 22 June 2023. EU Clinical Trials Register EudraCT Number: 2022-502890-40-00., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
36. Diuretic in Decompensated Heart Failure: With or Without Salt?
- Author
-
Martins WA
- Subjects
- Humans, Heart Failure drug therapy, Diuretics therapeutic use
- Published
- 2024
- Full Text
- View/download PDF
37. Diuretics use in the management of hypertension.
- Author
-
Morales-Olivas FJ
- Subjects
- Humans, Sodium Chloride Symporter Inhibitors adverse effects, Sodium Chloride Symporter Inhibitors therapeutic use, Sodium Chloride Symporter Inhibitors administration & dosage, Sodium Chloride Symporter Inhibitors pharmacology, Hydrochlorothiazide adverse effects, Hydrochlorothiazide administration & dosage, Hydrochlorothiazide therapeutic use, Chlorthalidone administration & dosage, Chlorthalidone therapeutic use, Chlorthalidone adverse effects, Female, Male, Drug Therapy, Combination, Hypertension drug therapy, Diuretics adverse effects, Diuretics administration & dosage, Diuretics therapeutic use, Diuretics pharmacology, Antihypertensive Agents adverse effects, Antihypertensive Agents administration & dosage, Antihypertensive Agents pharmacology, Antihypertensive Agents therapeutic use
- Abstract
Diuretics have been used for decades in the treatment of hypertension. Its efficacy has been demonstrated in numerous clinical trials. It is well known that the reduction in cardiovascular risk is a consequence of the reduction in blood pressure levels regardless of the drug used, but thiazide diuretics continue to be first-line drugs, especially in low doses and combined with other drugs. The debate on the advantages of using chlorthalidone or hydrochlorothiazide continues, however hydrochlorothiazide is drug most used and for which there is greater availability. The association with potassium-sparing diuretics increases the effectiveness and reduces the adverse reactions of thiazides. A new group of drugs, close to potassium-sparing diuretics, that antagonise aldosterone synthase are showing promising results as antihypertensives. There are no significant differences between men and women regarding the antihypertensive effect of thiazide diuretics., (Copyright © 2024 The Author. Publicado por Elsevier España, S.L.U. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
38. On-treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post-hoc analysis of TRANSFORM-HF.
- Author
-
Kittipibul V, Mentz RJ, Clare RM, Wojdyla DM, Anstrom KJ, Eisenstein EL, Ambrosy AP, Goyal P, Skopicki HA, Ketema F, Kim DY, Desvigne-Nickens P, Pitt B, Velazquez EJ, and Greene SJ
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Treatment Outcome, Diuretics therapeutic use, Furosemide therapeutic use, Furosemide administration & dosage, Heart Failure drug therapy, Heart Failure mortality, Torsemide therapeutic use, Hospitalization statistics & numerical data, Sodium Potassium Chloride Symporter Inhibitors therapeutic use
- Abstract
Aim: The TRANSFORM-HF trial demonstrated no significant outcome differences between torsemide and furosemide following hospitalization for heart failure (HF), but may have been impacted by non-adherence to the randomized diuretic. The current study sought to determine the treatment effect of torsemide versus furosemide using an on-treatment analysis inclusive of all randomized patients except those confirmed non-adherent to study diuretic., Methods and Results: TRANSFORM-HF was an open-label, pragmatic randomized trial of 2859 patients hospitalized for HF from June 2018 through March 2022. Patients were randomized to a loop diuretic strategy of torsemide versus furosemide with investigator-selected dosage. This post-hoc on-treatment analysis included all patients alive with either known or unknown diuretic status, and excluded patients confirmed to be non-adherent to study diuretic. This modified on-treatment definition was applied separately at time of hospital discharge and 30-day follow-up. All-cause mortality and hospitalization outcomes were assessed over 12 months. Overall, 2570 (89.9%) and 2374 (83.0%) patients were included in on-treatment analyses at discharge and 30-day follow-up, respectively. There was no significant difference in all-cause mortality between torsemide and furosemide in patients on-treatment at discharge (17.5% vs. 17.8%; hazard ratio [HR] 1.01 [95% confidence interval [CI] 0.83-1.22], p = 0.96) and at 30-day follow-up (14.5% vs. 15.0%; HR 1.02 [95% CI 0.81-1.27], p = 0.90). All-cause mortality or all-cause hospitalization was similar between torsemide and furosemide in patients who were on-treatment at discharge (58.3% vs. 61.3%; HR 0.92 [95% CI 0.82-1.03]) and 30-day follow-up (60.9% vs. 64.4%; HR 0.93 [95% CI 0.82-1.05]). In patients who were on-treatment at 30-day follow-up, there were 677 total hospitalizations in the torsemide group and 686 total hospitalizations in the furosemide group (rate ratio 0.99 [95% CI 0.86-1.14], p = 0.87)., Conclusions: In TRANSFORM-HF, a post-hoc on-treatment analysis did not meaningfully differ from the original trial results. Among those deemed compliant with the assigned diuretic, there remained no significant difference in mortality or hospitalization after HF hospitalization with a strategy of torsemide versus furosemide., Clinical Trail Registration: ClinicalTrials.gov Identifier: NCT03296813., (© 2024 European Society of Cardiology.)
- Published
- 2024
- Full Text
- View/download PDF
39. Ascites Is a Poor Prognostic Factor in Advanced Pancreatic Adenocarcinoma and May Be Undertreated: A Prospective Cohort Study.
- Author
-
Wang J, Cui Y, Osipov A, Gong J, Pandol S, Lo S, Nissen N, Abbas A, Levi A, and Hendifar A
- Subjects
- Humans, Male, Female, Prospective Studies, Aged, Middle Aged, Prognosis, Diuretics therapeutic use, Serum Albumin analysis, Serum Albumin metabolism, Aged, 80 and over, Catheters, Indwelling adverse effects, Ascites etiology, Pancreatic Neoplasms mortality, Pancreatic Neoplasms therapy, Pancreatic Neoplasms complications, Pancreatic Neoplasms pathology, Pancreatic Neoplasms diagnosis, Carcinoma, Pancreatic Ductal mortality, Carcinoma, Pancreatic Ductal therapy, Carcinoma, Pancreatic Ductal complications, Carcinoma, Pancreatic Ductal pathology
- Abstract
Introduction: Pancreatic ductal adenocarcinoma is associated with significant morbidity and mortality as most patients present with advanced disease. The development of ascites has been associated with poor outcomes and further characterization and contemporary management strategies are needed., Methods: A total of 437 patients enrolled in the Gastrointestinal Biobank at Cedars-Sinai Medical Center who had epithelial pancreatic malignancy were included in the prospective cohort group. Overall, 41.7% of patients included in this study developed ascites. Most patients with ascites (>80%) had high serum-ascites albumin gradient ascites. In both univariate and multivariate analysis, a history of ≥1 form of chemotherapy was significantly associated with ascites. Estimated median overall survival in patients with ascites was significantly lower than in patients without ascites, 473 days vs 573 days, and ascites had a hazard ratio of 1.37., Results: Patients with ascites who received diuretics and indwelling peritoneal catheter had an estimated median survival of 133 days from diagnosis of ascites, and those who received only the indwelling peritoneal catheter without diuretics had an estimated median survival of only 54 days. The estimated median survival from the diagnosis of ascites was 92 days, and the median time to puncture was 7 days. The median time from first tap to death was 45 days., Discussion: The use of diuretics is lower than would be expected for patients with pancreatic ductal adenocarcinoma with elevated serum-ascites albumin gradient. Other therapies such as beta blockers should be investigated in this subset of patients. The etiology of ascites in these patients is poorly understood, and further research is needed to establish treatment guidelines and improve outcomes., (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.)
- Published
- 2024
- Full Text
- View/download PDF
40. Navigating between Scylla and Charybdis: Diuretics during pregnancy - as much as needed, but the least possible.
- Author
-
Bauersachs J and Berliner D
- Subjects
- Humans, Pregnancy, Female, Heart Failure drug therapy, Diuretics therapeutic use, Pregnancy Complications, Cardiovascular drug therapy
- Published
- 2024
- Full Text
- View/download PDF
41. Effects of thiazides and new findings on kidney stones and dysglycemic side effects.
- Author
-
Bargagli M, Anderegg MA, and Fuster DG
- Subjects
- Humans, Animals, Glucose Intolerance chemically induced, Sodium Chloride Symporter Inhibitors adverse effects, Sodium Chloride Symporter Inhibitors therapeutic use, Diuretics adverse effects, Diuretics pharmacology, Diuretics therapeutic use, Kidney Calculi chemically induced, Kidney Calculi prevention & control, Thiazides therapeutic use, Thiazides adverse effects, Thiazides pharmacology
- Abstract
Thiazide and thiazide-like diuretics (thiazides) belong to the most frequently prescribed drugs worldwide. By virtue of their natriuretic and vasodilating properties, thiazides effectively lower blood pressure and prevent adverse cardiovascular outcomes. In addition, through their unique characteristic of reducing urine calcium, thiazides are also widely employed for the prevention of kidney stone recurrence and reduction of bone fracture risk. Since their introduction into clinical medicine in the early 1960s, thiazides have been recognized for their association with metabolic side effects, particularly impaired glucose tolerance, and new-onset diabetes mellitus. Numerous hypotheses have been advanced to explain thiazide-induced glucose intolerance, yet underlying mechanisms remain poorly defined. Regrettably, the lack of understanding and unpredictability of these side effects has prompted numerous physicians to refrain from prescribing these effective, inexpensive, and widely accessible drugs. In this review, we outline the pharmacology and mechanism of action of thiazides, highlight recent advances in the understanding of thiazide-induced glucose intolerance, and provide an up-to-date discussion on the role of thiazides in kidney stone prevention., (© 2024 The Authors. Acta Physiologica published by John Wiley & Sons Ltd on behalf of Scandinavian Physiological Society.)
- Published
- 2024
- Full Text
- View/download PDF
42. Reduced congestion and improved response to a fluid/sodium challenge in chronic heart failure patients after initiation of sacubitril/valsartan: The NATRIUM-HF study.
- Author
-
Mebazaa A, Davison BA, Biegus J, Edwards C, Murtagh G, Varounis C, Hayrapetyan H, Sisakian H, Ter-Grigoryan VR, Takagi K, Novosadova M, Ponikowski P, and Cotter G
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Treatment Outcome, Sodium, Diuresis drug effects, Diuretics therapeutic use, Diuretics administration & dosage, Prospective Studies, Valsartan therapeutic use, Biphenyl Compounds, Aminobutyrates therapeutic use, Aminobutyrates administration & dosage, Heart Failure drug therapy, Heart Failure physiopathology, Drug Combinations, Tetrazoles therapeutic use, Tetrazoles administration & dosage, Stroke Volume physiology, Stroke Volume drug effects, Natriuresis drug effects, Angiotensin Receptor Antagonists therapeutic use, Angiotensin Receptor Antagonists administration & dosage
- Abstract
Aims: The effects of initiating sacubitril/valsartan in patients with stable heart failure with reduced ejection fraction (HFrEF) on response to fluid and sodium expansion are unknown., Methods and Results: We have explored changes in natriuresis, diuresis, and congestion in response to the administration of intravenous fluid/sodium load in patients with HFrEF before as compared to after the initiation of sacubitril/valsartan. At baseline (before sacubitril/valsartan initiation) and 2 and 3 months after the initiation, patients underwent an evaluation that consisted of three phases of 3 h: the rest phase (0-3 h), the load phase (3-6 h) in which 1 L of intravenous Ringer solution was administered, and the diuretic phase (6-9 h) at the beginning of which furosemide was administered. Overall, 216 patients completed the study. In comparison to baseline values, at 2 and 3 months after sacubitril/valsartan initiation, patients' diuresis and natriuresis in response to Ringer administration significantly increased (mean difference: 38.8 [17.38] ml, p = 0.0040, and 9.6 [2.02] mmol, p < 0.0001, respectively). Symptoms and signs of congestion after the fluid/sodium challenge were significantly decreased at months 2 and 3 compared to baseline. Compared to baseline, there was also an increment of natriuresis after furosemide administration on sacubitril/valsartan (9.8 [5.13] mmol, p = 0.0167). There was a significant decrease in body weight in subsequent visits when compared to baseline values (-0.50 [-12.7, 7.4] kg at 2 months, and -0.75 [-15.9, 7.5] kg at 3 months; both p < 0.0001)., Conclusions: The initiation of sacubitril/valsartan in HFrEF patients was associated with improvements in natriuresis, diuresis, and weight loss and better clinical adaptation to potentially decongestive stressors., (© 2024 European Society of Cardiology.)
- Published
- 2024
- Full Text
- View/download PDF
43. Effect of antihypertensive agents on sleep apnea and ambulatory blood pressure in patients with hypertension: A randomized controlled trial.
- Author
-
Cichelero FT, Fuchs SC, Jorge JA, Martinez D, Oliveira GPF, Lucca MB, Oliveira ACT, and Fuchs FD
- Subjects
- Humans, Male, Female, Double-Blind Method, Middle Aged, Diuretics therapeutic use, Blood Pressure drug effects, Polysomnography drug effects, Aged, Hypertension drug therapy, Hypertension complications, Blood Pressure Monitoring, Ambulatory, Antihypertensive Agents therapeutic use, Chlorthalidone therapeutic use, Amlodipine therapeutic use, Sleep Apnea, Obstructive drug therapy, Sleep Apnea, Obstructive complications, Amiloride therapeutic use
- Abstract
Background: Obstructive sleep apnea (OSA) and hypertension are common conditions that may be linked through sympathetic activation and water retention. We hypothesized that diuretics, which reduce the body water content, may be more effective than amlodipine, a blood pressure (BP)-lowering agent implicated with edema, in controlling OSA in patients with hypertension. We also aimed to compare the effects of these treatments on ambulatory blood pressure monitoring (ABPM)., Methods: In a randomized, double-blind clinical trial, we compared the effects of chlorthalidone/amiloride 25/5 mg with amlodipine 10 mg on OSA measured by portable sleep monitor and BP measured by ABPM. The study included participants older than 40 who had moderate OSA (10-40 apneas/hour of sleep) and BP within the systolic range of 140-159 mmHg or diastolic range of 90-99 mmHg., Results: The individuals in the experimental groups were comparable in age, gender, and other relevant characteristics. Neither the combination of diuretics nor amlodipine alone reduced the AHI after 8 weeks of treatment (AHI 26.3 with diuretics and 25.0 with amlodipine. P = 0.713). Both treatments significantly lowered office, 24-h, and nighttime ABP, but the two groups had no significant difference., Conclusion: Chlorthalidone associated with amiloride and amlodipine are ineffective in decreasing the frequency of sleep apnea episodes in patients with moderate OSA and hypertension. Both treatments have comparable effects in lowering both office and ambulatory blood pressure. The notion that treatments could offer benefits for both OSA and hypertension remains to be demonstrated. TRIAL REGISTRATION CLINICALTRIALS., Gov Identifier: NCT01896661., Competing Interests: Declaration of competing interest On behalf of all the authors of this submission, I declare that we do not have any financial and personal relationships with other people or organizations that could inappropriately influence (bias) our work., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
44. Diuretics in pregnancy: Data from the ESC Registry of Pregnancy and Cardiac disease (ROPAC).
- Author
-
van der Zande JA, Greutmann M, Tobler D, Ramlakhan KP, Cornette JMJ, Ladouceur M, Collins N, Adamson D, Paruchuri VP, Hall R, Johnson MR, and Roos-Hesselink JW
- Subjects
- Humans, Female, Pregnancy, Adult, Prospective Studies, Furosemide adverse effects, Furosemide therapeutic use, Pregnancy Outcome epidemiology, Infant, Newborn, Heart Diseases epidemiology, Heart Failure epidemiology, Heart Failure drug therapy, Registries, Diuretics therapeutic use, Diuretics adverse effects, Pregnancy Complications, Cardiovascular drug therapy, Pregnancy Complications, Cardiovascular epidemiology
- Abstract
Aims: Data on diuretic use in pregnancy are limited and inconsistent, and consequently it remains unclear whether they can be used safely. Our study aims to evaluate the perinatal outcomes after in-utero diuretic exposure., Methods and Results: The Registry Of Pregnancy And Cardiac disease (ROPAC) is a prospective, global registry of pregnancies in women with heart disease. Outcomes were compared between women who used diuretics during pregnancy versus those who did not. Multivariable regression analysis was used to assess the impact of diuretic use on the occurrence of congenital anomalies and foetal growth. Diuretics were used in 382 (6.7%) of the 5739 ROPAC pregnancies, most often furosemide (86%). Age >35 years (odds ratio [OR] 1.5, 95% confidence interval [CI] 1.2-2.0), other cardiac medication use (OR 5.4, 95% CI 4.2-6.9), signs of heart failure (OR 1.7, 95% CI 1.2-2.2), estimated left ventricular ejection fraction <40% (OR 2.9, 95% CI 2.0-4.2), New York Heart Association class >II (OR 3.4, 95% CI 2.3-5.1), valvular heart disease (OR 6.3, 95% CI 4.7-8.3) and cardiomyopathy (OR 3.9, 95% CI 2.6-5.7) were associated with diuretic use during pregnancy. In multivariable analysis, diuretic use during the first trimester was not significantly associated with foetal or neonatal congenital anomalies (OR 1.3, 95% CI 0.7-2.6), and diuretic use during pregnancy was also not significantly associated with small for gestational age (OR 1.4, 95% CI 1.0-1.9)., Conclusions: Our study does not conclusively establish an association between diuretic use during pregnancy and adverse foetal outcomes. Given these findings, it is essential to assess the risk-benefit ratio on an individual basis to guide clinical decisions., (© 2024 The Author(s). European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
- Published
- 2024
- Full Text
- View/download PDF
45. Spot urinary sodium in CKD patients: correlation with 24h-excretion and evaluation of commonly used prediction equations.
- Author
-
Kurzhagen JT, Titze S, Büschges-Seraphin B, Schiffer M, Schneider MP, Eckardt KU, and Hilgers KF
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Urine Specimen Collection methods, Diuretics therapeutic use, Predictive Value of Tests, Urinalysis methods, Adult, Renal Insufficiency, Chronic urine, Sodium urine
- Abstract
Background: Salt intake in CKD patients can affect cardiovascular risk and kidney disease progression. Twenty-four hour (24h) urine collections are often used to investigate salt metabolism but are cumbersome to perform. We assessed urinary sodium (U-Na) concentration in spot urine samples and investigated the correlation with 24h U-Na excretion and concentration in CKD patients under nephrological care. Further, we studied the role of CKD stage and diuretics and evaluated the performance of commonly used formulas for the prediction of 24h U-Na excretion from spot urine samples., Methods: One hundred eight patients of the German Chronic Kidney Disease (GCKD) study were included. Each participant collected a 24h urine and two spot urine samples within the same period. The first spot urine sample (AM) was part of the second morning urine. The second urine sample was collected before dinner (PM). Patients were advised to take their medication as usual without changing dietary habits. U-Na concentrations in the two spot urine samples and their average ((AM + PM)/2) were correlated with U-Na concentration and total Na excretion in the 24h urine collections. Correlations were subsequently studied after stratification by CKD stage and diuretic intake. The usefulness of three commonly applied equations to estimate 24h U-Na excretion from spot urine samples (Kawasaki, Tanaka and Intersalt) was determined using Bland-Altman plots, analyses of sensitivity, specificity, as well as positive (PPV) and negative predictive values (NPV)., Results: Participants (42 women, 66 men) were on average (± SD) 62.2 (± 11.9) years old, with a mean serum creatinine of 1.6 (± 0.5) mg/dl. 95% had arterial hypertension, 37% diabetes mellitus and 55% were on diuretics. The best correlation with 24h U-Na total excretion was found for the PM spot U-Na sample. We also found strong correlations when comparing spot and 24h urine U-Na concentration. Correction of spot U-Na for U-creatinine did not improve strength of correlations. Neither CKD stage, nor intake of diuretics had significant impact on these correlations. All examined formulas revealed a significant mean bias. The lowest mean bias and the strongest correlation between estimated and measured U-Na excretion in 24h were obtained using the Tanaka-formula. Also, application of the Tanaka-formula with PM U-Na provided best sensitivity, specificity, PPV and NPV to estimate U-Na excretion > 4g/d corresponding to a salt consumption > 10g/d., Conclusion: U-Na concentration of spot urine samples correlated with 24h U-Na excretion especially when PM spot U-Na was used. However, correlation coefficients were relatively low. Neither CKD stage nor intake of diuretics appeared to have an influence on these correlations. There was a significant bias for all tested formulas with the Tanaka-formula providing the strongest correlation with measured 24h U-Na excretion. In summary, using spot urine samples together with the Tanaka-formula in epidemiological studies appears feasible to determine associations between approximate salt intake and outcomes in CKD patients. However, the usefulness of spot-urine samples to guide and monitor salt consumption in individual patients remains limited., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
46. The acute effects of furosemide in acute heart failure assessed by remote dielectric sensing. A protocol.
- Author
-
El Caidi NO, Lukoschewitz JD, Nielsen OW, Hove J, Seven E, Dixen U, Grund F, Petersen M, Foss NB, and Grand J
- Subjects
- Humans, Prospective Studies, Diuretics therapeutic use, Acute Disease, Remote Sensing Technology methods, Female, Male, Sodium Potassium Chloride Symporter Inhibitors therapeutic use, Furosemide therapeutic use, Furosemide administration & dosage, Heart Failure drug therapy, Heart Failure physiopathology, Pulmonary Edema drug therapy
- Abstract
Introduction: Intravenous loop diuretics have been a key component in treating pulmonary oedema since the 1960s and have a Class 1 recommendation in the 2021 guidelines for acute heart failure (AHF). While the diuretic effect of loop diuretics is well established, it remains unclear how furosemide influences pulmonary congestion and cardiac filling pressures in the hyperacute phase before significant diuresis occurs., Methods: This was a prospective study of adult patients with AHF and objective signs of pulmonary congestion admitted to the cardiac ward. Remote dielectric sensing (ReDS) will directly measure lung fluid content, and cardiac filling pressures will be assessed by echocardiography with Doppler and strain analysis., Conclusions: This study will examine if furosemide leads to a hyperacute reduction in pulmonary congestion assessed by ReDS independent of diuretic effects in patients with AHF. We hypothesise that the haemodynamic effect of furosemide shown on pulmonary congestion may explain the subjective instant relief in patients with AHF receiving furosemide., Funding: Dr. Grand's salary during this project is supported by a research grant from the Danish Cardiovascular Academy funded by Novo Nordisk Foundation grant number NNF20SA0067242 and by the Danish Heart Foundation., Trial Registration: This protocol was approved by the Scientific Ethical Committee, H-23029822, and the Danish Data Protection Agency P-2013-14703. The protocol was registered with ClinicalTrial.org on 29 August 2023 (Identifier: NCT06024889)., (Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.)
- Published
- 2024
- Full Text
- View/download PDF
47. Evaluation and Management of Hyponatremia in Heart Failure.
- Author
-
Mondellini GM and Verbrugge FH
- Subjects
- Humans, Diuretics therapeutic use, Disease Management, Hyponatremia therapy, Hyponatremia physiopathology, Hyponatremia etiology, Heart Failure physiopathology, Heart Failure complications, Heart Failure therapy
- Abstract
Purpose of Review: To provide a contemporary overview of the pathophysiology, evaluation, and treatment of hyponatremia in heart failure (HF)., Recent Findings: Potassium and magnesium losses due to poor nutritional intake and treatment with diuretics cause an intracellular sodium shift in HF that may contribute to hyponatremia. Impaired renal blood flow leading to a lower glomerular filtration rate and increased proximal tubular reabsorption lead to an impaired tubular flux through diluting distal segments of the nephron, compromising electrolyte-free water excretion. Hyponatremia in HF is typically a condition of impaired water excretion by the kidneys on a background of potassium and magnesium depletion. While those cations can and should be easily repleted, further treatment should mainly focus on improving the underlying HF and hemodynamics, while addressing congestion. For decongestive treatment, proximally acting diuretics such as sodium-glucose co-transporter-2 inhibitors, acetazolamide, and loop diuretics are the preferred options., (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
48. Renal function and natriuresis-guided diuretic therapy - a pre-specified analysis from the PUSH-AHF trial.
- Author
-
Damman K, Beldhuis IE, van der Meer P, Krikken JA, Coster JE, Nieuwland W, van Veldhuisen DJ, Voors AA, and Ter Maaten JM
- Subjects
- Humans, Female, Male, Aged, Middle Aged, Diuretics therapeutic use, Diuretics administration & dosage, Sodium Potassium Chloride Symporter Inhibitors therapeutic use, Sodium Potassium Chloride Symporter Inhibitors administration & dosage, Treatment Outcome, Acute Disease, Creatinine blood, Glomerular Filtration Rate drug effects, Glomerular Filtration Rate physiology, Heart Failure drug therapy, Heart Failure physiopathology, Natriuresis drug effects
- Abstract
Aim: In a randomized controlled trial, we recently showed that a natriuresis-guided diuretic approach improved natriuresis and diuresis in patients with acute heart failure (HF). In this pre-specified analysis, we investigated the association between (worsening) renal function, outcomes and the effect of intensive natriuresis-guided loop diuretic therapy as compared with standard of care., Methods and Results: The Pragmatic Urinary Sodium-based algoritHm in Acute Heart Failure (PUSH-AHF) trial randomized patients to natriuresis-guided diuretic therapy or standard of care. Serum creatinine and estimated glomerular filtration rate (eGFR) were assessed at fixed timepoints, and worsening renal function (WRF) was assessed at 72 h. The primary outcome was the interaction between randomized treatment allocation, baseline eGFR and the dual primary outcome of PUSH-AHF: total natriuresis at 24 h and time to all-cause mortality or HF rehospitalization at 180 days. In 309 patients, median baseline eGFR was 53 (35-73) ml/min/1.73 m
2 , and 58% had eGFR <60 ml/min/1.73 m2 . Baseline eGFR did not significantly modify the treatment effect of natriuresis-guided diuretic therapy on natriuresis at 24 h (p for interaction = 0.730). However, baseline eGFR significantly modified the effect on all-cause mortality and HF rehospitalization (p for interaction = 0.017): the risk of this second primary outcome was lower in patients with lower eGFR who were randomized to the natriuresis-guided group. In the natriuresis-guided arm, eGFR decreased more (-11.0 vs. -6.91 ml/min/1.73 m2 ; p = 0.002) during the first 3 days, but this effect was attenuated at discharge (-10.3 vs. -8.69 ml/min/1.73 m2 ; p = 0.38). WRF was more frequently observed in patients randomized to natriuresis-guided treatment, but was not associated with worse clinical outcomes., Conclusions: Natriuresis-guided diuretic treatment improved diuresis and natriuresis irrespective of baseline eGFR and occurrence of WRF, was effective even in patients with low eGFR, and the observed effect on eGFR was transient and not associated with worse clinical outcomes., (© 2024 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)- Published
- 2024
- Full Text
- View/download PDF
49. Effect of periprocedural furosemide-induced diuresis with matched isotonic intravenous hydration in patients with chronic kidney disease undergoing transcatheter aortic valve implantation.
- Author
-
Voigtländer-Buschmann L, Schäfer S, Schmidt-Lauber C, Weimann J, Shenas M, Giraldo Cortes J, Kuta PM, Zeller T, Twerenbold R, Seiffert M, Schofer N, Schneeberger Y, Schäfer A, Schirmer J, Reichenspurner H, Blankenberg S, Conradi L, and Schäfer U
- Subjects
- Humans, Female, Male, Aged, 80 and over, Aged, Fluid Therapy methods, Treatment Outcome, Diuresis drug effects, Diuretics administration & dosage, Diuretics therapeutic use, Contrast Media adverse effects, Contrast Media administration & dosage, Postoperative Complications prevention & control, Postoperative Complications epidemiology, Risk Factors, Transcatheter Aortic Valve Replacement adverse effects, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic physiopathology, Aortic Valve Stenosis surgery, Furosemide administration & dosage, Acute Kidney Injury prevention & control, Acute Kidney Injury chemically induced, Acute Kidney Injury etiology
- Abstract
Background: Acute kidney injury (AKI) after transcatheter aortic valve implantation (TAVI) is a serious complication which is associated with increased mortality. The RenalGuard system was developed to reduce the risk of AKI after contrast media exposition by furosemide-induced diuresis with matched isotonic intravenous hydration. The aim of this study was to examine the effect of the RenalGuard system on the occurrence of AKI after TAVI in patients with chronic kidney disease., Methods: The present study is a single-center randomized trial including patients with severe aortic valve stenosis undergoing TAVI. Overall, a total of 100 patients treated by TAVI between January 2017 and August 2018 were randomly assigned to a periprocedural treatment with the RenalGuard system or standard treatment by pre- and postprocedural intravenous hydration. Primary endpoint was the occurrence of AKI after TAVI, and secondary endpoints were assessed according to valve academic research consortium 2 criteria., Results: Overall, the prevalence of AKI was 18.4% (n = 18). The majority of these patients developed mild AKI according to stage 1. Comparing RenalGuard to standard therapy, no significant differences were observed in the occurrence of AKI (RenalGuard: 21.3%; control group: 15.7%; p = 0.651). In addition, there were no differences between the groups with regard to 30-day and 12-month mortality and procedure-associated complication rates., Conclusion: In this randomized trial, we did not detect a reduction in AKI after TAVI by using the RenalGuard system. A substantial number of patients with chronic kidney disease developed AKI after TAVI, whereas the majority presented with mild AKI according to stage 1 (ClinicalTrials.gov number NCT04537325)., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
50. Preoperative use of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diuretics increases the risk of dehydration after ileostomy formation: population-based cohort study.
- Author
-
de la Motte L, Nordenvall C, Martling A, and Buchli C
- Subjects
- Humans, Male, Female, Aged, Sweden epidemiology, Middle Aged, Risk Factors, Rectal Neoplasms surgery, Postoperative Complications epidemiology, Postoperative Complications etiology, Cohort Studies, Aged, 80 and over, Incidence, Registries, Preoperative Care methods, Angiotensin Receptor Antagonists therapeutic use, Angiotensin Receptor Antagonists adverse effects, Angiotensin-Converting Enzyme Inhibitors adverse effects, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Ileostomy adverse effects, Dehydration epidemiology, Patient Readmission statistics & numerical data, Diuretics adverse effects, Diuretics therapeutic use
- Abstract
Background: Readmission rates following ileostomy formation are high. Dehydration and consecutive renal failure are common causes of readmission, potentially pronounced by drugs affecting the homeostasis. The aim of the study was to assess the risk of dehydration after ileostomy formation in patients treated with angiotensin-converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB) or diuretics., Method: This nationwide population-based cohort study used data derived from the Colorectal Cancer Data Base of several Swedish healthcare registers. The study included all patients operated on with elective anterior resection and temporary ileostomy for rectal cancer clinically staged I-III in Sweden in 2007-2016. Exposure was at least two dispensations of ACEI, ARB or diuretics within 1 year prior to surgery. Outcome was 90-day readmission due to dehydration including acute renal failure., Results: In total, 3252 patients were included with 1173 (36.1%) exposed to ACEI, ARB or diuretics. The cumulative incidence for 90-day readmission due to dehydration was 29.0% (151 of 520) for exposed versus 13.8% (98 of 712) for unexposed. The proportion of readmissions due to any reason was 44.3% (520 of 1173) for exposed compared to 34.2% (712 of 2079) for unexposed. The incidence rate ratio for readmission due to dehydration was 2.83 (95% c.i. 2.21 to 3.63, P < 0.001). The hazard rate ratio was 2.45 (95% c.i. 1.83 to 3.27, P < 0.001) after adjusting for age, gender and comorbidity., Conclusion: Medication with ACEI, ARB or diuretics defines a vulnerable patient group with increased risk of readmission due to dehydration after ileostomy formation., (© The Author(s) 2024. Published by Oxford University Press on behalf of BJS Foundation Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.